FV-100

FV-100

Names
IUPAC name 3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Systematic IUPAC name 3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Other names Cf1743
Identifiers
CAS Number	956483-02-6 Y
3D model (JSmol)	Interactive image
PubChem CID	493485
UNII	0NJ5F6D4U7 Y
CompTox Dashboard (EPA)	DTXSID60185781
SMILES CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
Properties
Chemical formula	C22H26N2O5
Molar mass	398.459 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. It has reached Phase III clinical trials.